文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

局限性前列腺癌局灶近距离放疗的中期结局

Focal Brachytherapy for Localized Prostate Cancer: Midterm Outcomes.
PubMed 文献 · Pract Radiat Oncol · 2021-01-07

本研究回顾性纳入39例低至中危局限性前列腺癌患者,2010至2015年接受局灶近距离放疗(F-BT),处方剂量145 Gy,中位随访65个月。5年生化无复发生存率96.8%,无病生存率79.5%,总生存率100%,未见晚期泌尿、性功能或直肠毒性。

要点

  • F-BT后24个月活检阴性率79%,阳性7例均位于治疗体积外。
  • 5年生化无复发生存率96.8%,无病生存率79.5%,总生存率100%。
  • 未见晚期泌尿、性功能或直肠毒性,补救治疗耐受良好。

核心结论

  • F-BT是经过选择的低至中危局限性前列腺癌患者安全有效的治疗方式。

研究设计与样本

  • 回顾性研究,纳入39例2010至2015年接受F-BT的低至中危局限性前列腺癌患者,处方剂量145 Gy。

主要发现

  • 平均随访65个月(范围43-104个月),24个月后34例接受对照活检、5例拒绝。
  • 活检阴性27例(79%),阳性7例(21%),均位于治疗体积外。
  • 5年生化无复发生存率96.8%±0.032%,无病生存率79.5%±0.076%,总生存率100%。
  • 术后2个月国际前列腺症状评分(IPSS)均值显著高于初始(P=.0003),此后无显著差异。
  • 未见晚期泌尿、性功能或直肠毒性;随访3.4年时可进行补救治疗且耐受良好。

关键数值与推荐

  • 失败定义为治疗区域内存在任何残留前列腺癌。
  • 双侧P值<.05认为有统计学显著性。

临床怎么用

  • 对于经过选择的低至中危局限性前列腺癌患者,F-BT可作为局灶治疗选项。
  • 治疗后需进行对照活检评估局部控制,并监测IPSS变化。

局限性

  • 回顾性研究设计,缺乏随机化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Focal brachytherapy (F-BT) is a suitable technique for focal therapy in localized prostate cancer. It has the ability to adapt the seed implantation to the volume and location of the tumor. The aim of this study was to assess F-BT oncologic, functional, and toxicity midterm outcomes in men who underwent prostate cancer treatment. METHODS AND MATERIALS: The study included 39 men with low- to intermediate-risk prostate cancer treated with F-BT between 2010 and 2015. The dose prescription was 145 Gy. Failure was defined as the presence of any residual prostate cancer in the treated area. The primary and secondary endpoints were the F-BT oncologic and functional outcomes, respectively. A 2-sided P value < .05 indicated statistical significance. RESULTS: The mean follow-up time was 65 months (range, 43-104 months). After 24 months, 34 patients underwent control biopsies and 5 patients refused. The biopsies were negative in 27 cases (79%) and positive in 7 cases (21%), all outside the volume treated. Biochemical relapse-free survival at 5 years, disease-free survival, and overall survival were 96.8% ± 0.032%, 79.5% ± 0.076%, and 100%, respectively. The mean International Prostate Symptom Score at 2 months was significantly higher than initially (P = .0003), with no significant difference later. No late urinary, sexual, or rectal toxicity was observed. Salvage treatment was possible with good tolerance at 3.4 years of follow-up. Limitations of this study include the retrospective nature and lack of randomization. CONCLUSIONS: F-BT is a safe and effective treatment for selected patients presenting with low- or intermediate-risk localized prostate cancer.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ta MH, Nunes-Silva I, Barret E, et al. Focal Brachytherapy for Localized Prostate Cancer: Midterm Outcomes. Pract Radiat Oncol. 2021. PMID: 33422681. doi:10.1016/j.prro.2020.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。